Laparoscopic donor nephrectomy for the pediatric recipient population: Risk factors for adverse outcomes

Pediatric Transplantation
Ashley E WaltherJaimie D Nathan

Abstract

Kidney transplantation is the optimal treatment of ESRD in children. Some studies have reported inferior outcomes in recipients of LDN allografts who are ≤ 5 yr of age. We performed a retrospective review of pediatric recipient outcomes of 110 LDN allografts at our institution and examined predictors of adverse outcomes. Subgroup analysis was performed by dividing recipients into three age categories: 0-5 yr, 6-17 yr, and ≥ 18 yr. There was no significant difference between incidences of DGF or ARE between groups. Kaplan-Meier analysis demonstrated 100% allograft survival in 0- to 5-yr-old recipients, nearly reaching statistical significance (p = 0.07) for outcome superior to that of the two older age groups. Pretransplant HD was associated with increased risk of DGF (p = 0.05). Significant risk factors for ARE were recipient weight >15 kg (p = 0.033) and multiple renal arteries (p = 0.047). Previous ARE was associated with an increased risk of allograft failure (p = 0.02). LDN is not associated with increased risk of DGF, ARE, or allograft failure in the youngest recipients. These findings support an aggressive pursuit of preemptive transplantation even in the youngest pediatric allograft recipients.

References

Dec 1, 1996·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·C GuyotJ L André
Jul 26, 2002·Journal of the American Society of Nephrology : JASN·Bertram L KasiskeDavid Gilbertson
Sep 18, 2002·Kidney International·Jon J SnyderAllan J Collins
Nov 28, 2002·Pediatric Transplantation·Jodi M SmithUNKNOWN North American Pediatric Renal Transplant Cooperative Study
Jan 31, 2004·Urology·Harrison M AbrahamsMarshall L Stoller
Feb 12, 2004·Pediatric Transplantation·Richard J ShawMinnie Sarwal
Jan 8, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Christoph TroppmannRichard V Perez
May 13, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Jonathan T CarterAndrew M Posselt
Sep 16, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Jennifer S SingerPeter Schulam
Mar 14, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·K SolezJ J Weening
Apr 13, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S HorslenJ C Magee
May 26, 2007·Transplantation Proceedings·H A FettouhI A Fettouh
Dec 11, 2008·Pediatric Transplantation·Stefano GiulianiGiovanni Franco Zanon
Nov 18, 2009·Transplantation Proceedings·K M HaradaJ O Medina-Pestana
Feb 4, 2010·Current Opinion in Pediatrics·Ashima Gulati, Minnie M Sarwal
Jun 30, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Pankaj ChandakNizam Mamode

❮ Previous
Next ❯

Citations

Mar 8, 2017·Transplant International : Official Journal of the European Society for Organ Transplantation·Josianne C H B M LuijtenElisabeth A M Cornelissen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.